Background: Standard pharmacotherapy for patients with heart failure with reduced ejection fraction (HFrEF) comprises “quadruple therapy” with a renin–angiotensin system inhibitor, a β-blocker, a ...

Conclusion: Our data show that RAS activation promotes NO production in podocytes, mainly via the AT2R pathway. NO is crucial for Ca 2+ control in podocytes and lamellipodia formation, suggesting the ...

The Renin-Angiotensin System (RAS) is a hormonal cascade intricately involved in regulating hydro electrolyte homeostasis and blood pressure control. The Angiotensin II peptide (ANGII) is the main and ...

Many of the drugs used to treat high blood pressure work on the renin-angiotensin pathway, so zilebesiran's mechanism – blocking a precursor to angiotensin – is pretty well validated.